Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination

被引:9
作者
Abdallah, Al-Ola [1 ,2 ]
Mahmoudjafari, Zahra [2 ,3 ]
Atieh, Tahani [3 ]
Ahmed, Nausheen [1 ,2 ]
Cui, Wei [2 ,3 ]
Shune, Leyla [1 ,2 ]
Mohan, Meera [2 ,4 ]
McGuirk, Joseph [1 ]
Remker, Cassie [3 ]
Foss, Margaret [3 ]
Karloff, Ellie [3 ]
Fitch, Heather [3 ]
Atrash, Shebli [2 ,5 ]
机构
[1] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS 66205 USA
[2] US Myeloma Res Innovat Res Collaborat USMIRC, Westwood, KS USA
[3] Univ Kansas, Med Ctr, Westwood, KS USA
[4] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA
[5] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA
关键词
mRNA vaccine; multiple myeloma; plasma cell disorder; SARS-CoV-2; CLINICAL CHARACTERISTICS; COVID-19; CANCER;
D O I
10.1111/ejh.13826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many patients with plasma cell disorder (PCD) on active treatment with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require hospitalization, with an increased mortality rate over healthy adults. The FDA approved two mRNA vaccines against SARS-CoV-2: BNT162b2 and mRNA-1273. To assess the efficacy of vaccination in patients with PCD, retrospectively, we identified all patients on active treatment. A total of 149 patients were included. Neutralizing antibodies (NAbs) levels against SARS-CoV-2 adequate, intermediate, and no response were observed in 42%, 32%, and 26%, respectively. Low NAbs were seen in patients on daratumumab combinations or anti-BCMA therapy, low lymphocytes, and low IgG levels. Twenty-three (15%) patients have SARS CoV-2, while 8% required hospitalization, majority of these patients had intermediate or no response based on NAbs levels. Therefore, checking NAbs may be clinically helpful in identifying patients' responses. Further prospective studies should ascertain the value of a third vaccine dose in this population.
引用
收藏
页码:458 / 464
页数:7
相关论文
共 19 条
[1]   Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma [J].
Bird, Sarah ;
Panopoulou, Aikaterini ;
Shea, Robyn L. ;
Tsui, Micky ;
Saso, Radovan ;
Sud, Amit ;
West, Sharon ;
Smith, Katy ;
Barwood, John ;
Kaczmarek, Ewa ;
Panlaqui, Carmela ;
Kaiser, Martin ;
Stern, Simon ;
Pawlyn, Charlotte ;
Boyd, Kevin .
LANCET HAEMATOLOGY, 2021, 8 (06) :E389-E392
[2]   Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set [J].
Chari, Ajai ;
Samur, Mehmet Kemal ;
Martinez-Lopez, Joaquin ;
Cook, Gordon ;
Biran, Noa ;
Yong, Kwee ;
Hungria, Vania ;
Engelhardt, Monika ;
Gay, Francesca ;
Feria, Ana Garcia ;
Oliva, Stefania ;
Oostvogels, Rimke ;
Gozzetti, Alessandro ;
Rosenbaum, Cara ;
Kumar, Shaji ;
Stadtmauer, Edward A. ;
Einsele, Hermann ;
Beksac, Meral ;
Weisel, Katja ;
Anderson, Kenneth C. ;
Mateos, Maria-Victoria ;
Moreau, Philippe ;
San-Miguel, Jesus ;
Munshi, Nikhil C. ;
Avet-Loiseau, Herve .
BLOOD, 2020, 136 (26) :3033-3040
[3]  
Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]
[4]   A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial [J].
Dumontet, Charles ;
Hulin, Cyrille ;
Dimopoulos, Meletios A. ;
Belch, Andrew ;
Dispenzieri, Angela ;
Ludwig, Heinz ;
Rodon, Philippe ;
Van Droogenbroeck, Jan ;
Qiu, Lugui ;
Cavo, Michele ;
Van de Velde, Ann ;
Lahuerta, Juan Jose ;
Allangba, Olivier ;
Lee, Jae Hoon ;
Boyle, Eileen ;
Perrot, Aurore ;
Moreau, Philippe ;
Manier, Salomon ;
Attal, Michel ;
Roussel, Murielle ;
Mohty, Mohamad ;
Mary, Jean Yves ;
Civet, Alexandre ;
Costa, Bruno ;
Tinel, Antoine ;
Gaston-Mathe, Yann ;
Facon, Thierry .
LEUKEMIA, 2018, 32 (06) :1404-1413
[5]   Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase [J].
El Sahly, H. M. ;
Baden, L. R. ;
Essink, B. ;
Doblecki-Lewis, S. ;
Martin, J. M. ;
Anderson, E. J. ;
Campbell, T. B. ;
Clark, J. ;
Jackson, L. A. ;
Fichtenbaum, C. J. ;
Zervos, M. ;
Rankin, B. ;
Eder, F. ;
Feldman, G. ;
Kennelly, C. ;
Han-Conrad, L. ;
Levin, M. ;
Neuzil, K. M. ;
Corey, L. ;
Gilbert, P. ;
Janes, H. ;
Follmann, D. ;
Marovich, M. ;
Polakowski, L. ;
Mascola, J. R. ;
Ledgerwood, J. E. ;
Graham, B. S. ;
August, A. ;
Clouting, H. ;
Deng, W. ;
Han, S. ;
Leav, B. ;
Manzo, D. ;
Pajon, R. ;
Schodel, F. ;
Tomassini, J. E. ;
Zhou, H. ;
Miller, J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (19) :1774-1785
[6]   Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany [J].
Engelhardt, Monika ;
Shoumariyeh, Khalid ;
Roesner, Amelie ;
Ihorst, Gabriele ;
Biavasco, Francesca ;
Meckel, Katharina ;
von Metzler, Ivana ;
Theurich, Sebastian ;
Hebart, Holger ;
Grube, Matthias ;
Kull, Miriam ;
Bassermann, Florian ;
Schaefer-Eckart, Kerstin ;
Hoferer, Anette ;
Einsele, Hermann ;
Rasche, Leo ;
Waesch, Ralph .
HAEMATOLOGICA, 2020, 105 (12) :2872-2878
[7]  
fda, EMERGENCY PREPAREDNE
[8]   Organ-specific manifestations of COVID-19 infection [J].
Gavriatopoulou, Maria ;
Korompoki, Eleni ;
Fotiou, Despina ;
Ntanasis-Stathopoulos, Ioannis ;
Psaltopoulou, Theodora ;
Kastritis, Efstathios ;
Terpos, Evangelos ;
Dimopoulos, Meletios A. .
CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 20 (04) :493-506
[9]   Actors on the Scene: Immune Cells in the Myeloma Niche [J].
Leone, Patrizia ;
Solimando, Antonio Giovanni ;
Malerba, Eleonora ;
Fasano, Rossella ;
Buonavoglia, Alessio ;
Pappagallo, Fabrizio ;
De Re, Valli ;
Argentiero, Antonella ;
Silvestris, Nicola ;
Vacca, Angelo ;
Racanelli, Vito .
FRONTIERS IN ONCOLOGY, 2020, 10 :1-15
[10]   Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality [J].
Martinez-Lopez, Joaquin ;
Mateos, Maria-Victoria ;
Encinas, Cristina ;
Sureda, Anna ;
Angel Hernandez-Rivas, Jose ;
Lopez de la Guia, Ana ;
Conde, Diego ;
Krsnik, Isabel ;
Prieto, Elena ;
Riaza Grau, Rosalia ;
Gironella, Mercedes ;
Jesus Blanchard, Maria ;
Caminos, Nerea ;
Fernandez de Larrea, Carlos ;
Alicia Senin, Maria ;
Escalante, Fernando ;
Enrique de la Puerta, Jose ;
Gimenez, Eugenio ;
Martinez-Barranco, Pilar ;
Jose Mateos, Juan ;
Felipe Casado, Luis ;
Blad, Joan ;
Jose Lahuerta, Juan ;
de la Cruz, Javier ;
San-Miguel, Jesus .
BLOOD CANCER JOURNAL, 2020, 10 (10)